Jun 08, 2023 / 05:00PM GMT
Matt Galle - Jefferies - Analyst
Hi everyone, my name is Matt Galle, I'm part of the Jefferies healthcare banking team. It's my pleasure to welcome you to the Jefferies Global Healthcare Conference. With us today we have Martin Welschof, part of BioInvent, CEO of BioInvent, here to give you a presentation. I'm going to turn it over to him. Thank you.
Martin Welschof - BioInvent International AB - CEO
Thank you, Matt. And welcome, everybody. So this is our forward-looking statement and I will start with a quick snapshot of BioInvent.
So at BioInvent we are translating cancer biology into innovative immuno-oncology therapies and we are actually pushing ahead with a broad clinical portfolio, currently having five clinical programs running, soon six. And all these programs have been generated in-house since we are quite an integrated company. So we have a research engine that discovers targets and antibodies, we have our own manufacturing in-house, we can do up to 1,000 liter GMP, and obviously clinical development.
The technology that we use for
BioInvent International AB at Jefferies Healthcare Conference Transcript
Jun 08, 2023
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers